Donald Greco, MD
Pain Medicine · Rancho Mirage, CANPI 1740416767
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,513 of the $2,927 with a category attached, or 85.9%. 9 manufacturers reported payments, led by SPR Therapeutics, Inc at 53.5% of the total. Reporting peaked in 2022 at $1,077 and has fallen 92.1% since, to $85 in 2025.
Across 49 payments — averaging $59.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$2K
- Nevro Corp.$913
- Boston Scientific$238
- Abbott$93
- Daiichi Sankyo Inc.$31
- Pacira Therapeutics, Inc.$31
- plus $56 from 3 others
What the payments were for
- Travel & lodging$41314%
- Food & beverage$2,51386%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 13 | $1,565 |
| Nevro Corp. | 20 | $913 |
| Boston Scientific | 6 | $238 |
| Abbott | 4 | $93 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Pacira Therapeutics, Inc. | 1 | $31 |
| Globus Medical | 1 | $28 |
| Fidia Pharma USA Inc. | 1 | $17 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,927 in reported general payments places this provider in the 60th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 87 | $20,212 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 85 | $12,831 |
| MovantikNaloxegol Oxalate | 13 | $5,247 |
| Gabapentin | 204 | $3,115 |
| Buprenorphine Hcl | 67 | $2,726 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $2,171 |
| Celecoxib | 19 | $1,641 |
| Duloxetine Hcl | 96 | $1,441 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 56 | $1,426 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 32 | $777 |
| Baclofen | 38 | $582 |
| Tramadol Hcl | 106 | $484 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $440 |
| Oxycodone Hcl | 25 | $417 |
| Ondansetron OdtOndansetron | 14 | $356 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Rancho Mirage
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.